Immuron Ltd — Regulatory Filings 2012

May 13, 2012

ABN: 80 063 114 045 Level 1, 39 Leveson Street North Melbourne, Vic 3051 Tel: +61 3 8637 1107 Fax: +61 3 9328 1675 www.immuron.com

==> picture [193 x 41] intentionally omitted <==

IMMURON’S SECOND TRAVELAN ASIA DISTRIBUTION AGREEMENT

• Agreement with distributor to sell Travelan in Singapore, Malaysia and Brunei

• Regulatory submission preparations commenced

14 May 2012, Melbourne, Australia : Australian biopharmaceutical company Immuron Limited (ASX: IMC), manufacturer of Travelan®, has entered into an agreement with Singaporean company Ziwell Medical (S) Pte Ltd for the distribution of Travelan in Singapore, Malaysia and Brunei.

Travelan is clinically-proven with 90% efficacy to prevent the main cause of travellers’ diarrhoea. Travellers’ diarrhoea is endemic in each of these countries which, according to the World Tourism Organization, hosted approximately 34 million travellers in 2010. This is in addition to the local resident population of approximately 33 million people.

Under the agreement, Ziwell Medical is required to attain regulatory approval for the sale of Travelan in its licensed countries and to sell specified minimum volumes. There is also an agreed timetable for the launch and sales of Travelan in the licensed countries.

Ziwell Medical is a pharmaceutical and medical wholesale importer and distributor. Its product portfolio comprises a range of over-the-counter products including for gastro-intestinal health. Travelan fits very well with Ziwell Medical’s existing portfolio and capabilities.

“This news builds on the first south east Asia distribution agreement announced last week. Immuron is determined to capture the full value of our extremely effective Travelan product in Asia and elsewhere. Ziwell Medical has rich experience with specialty products and we have every confidence that it will succeed in building a strong Travelan presence in its licensed countries,” ” said Joe Baini, Immuron’s Chief Executive Officer.

“

Ziwell Medical Managing Director, Mr Yeo Siew Meng said: “Travelan is a unique and excellent product. We intend to strongly market Travelan throughout our network and assigned territories.”

Contact

Joe Baini – Chief Executive Officer +61 3 8637 1107

Rudi Michelson Monsoon Communications +61 3 9620 3333 +61 411 402 737

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH), and the prevention of influenza. Immuron has one product in the market, Travelan, for preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), the University of Melbourne and Monash University (Australia).

About Ziwell Medical

Ziwell Medical is a pharmaceutical and medical wholesale importer and distributor since 1992. It focuses on the sales and distribution of quality pharmaceuticals, medical devices and healthproducts in Singapore, Malaysia and Brunei. Ziwell Medical is an exclusive distributor for suppliers and manufacturers in the healthcare industry, providing services to match the needs of medical institutions and its principals.